Edu Butyrose
  • Responsabile scientifico
  • Articoli
    • BARRIERA EPITELIALE INTESTINALE
    • BUTIRRATO
    • COVID-19
    • GVHD – Graft-versus-Host Disease / Malattia del trapianto contro l’ospite
    • IBS
    • IBD
    • IDROSADENITE SUPPURATIVA
    • LINEE GUIDA
    • MALATTIE METABOLICHE
    • MALATTIA DIVERTICOLARE
    • RADIOTERAPIA
    • RIGENERAZIONE CUTANEA
  • Interviste
  • Eventi
  • Studi in corso
  • Riviste
  • Documenti utili
  • LSC
  • SILA
  • Logout
Seleziona una pagina
Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases—Current Clinical Approach

Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases—Current Clinical Approach

da admin | Ott 2, 2026 | MALATTIA DIVERTICOLARE

Non hai il permesso di visualizzare questo contenuto.
Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases—Current Clinical Approach

10 Pearls for Clinical Practice in Disorders of Gut-Brain Interaction

da admin | Ott 2, 2026 | DGBI 2026 DISORDERS GUT BRAIN INTERACTION

10 Pearls for Clinical Practice in Disorders of Gut-Brain Interaction Lin Chang, Heidi M. Staudacher, Sarah Ballou and Giovanni Barbara The American Journal of Gastroenterology Visualizza...
Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases—Current Clinical Approach

Disorders of Gut–Brain Interaction and the Rome V Process

da admin | Ott 2, 2026 | DGBI 2026 DISORDERS GUT BRAIN INTERACTION

Disorders of Gut–Brain Interaction and the Rome V Process Douglas A. Drossman, Lin Chang, Jan Tack Gastroenterology Vol. 170, Iss. 6 Visualizza...
Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases—Current Clinical Approach

Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut–Brain Interaction

da admin | Ott 2, 2026 | DGBI 2026 DISORDERS GUT BRAIN INTERACTION

Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut–Brain Interaction Michael Camilleri, Giovanni Sarnelli, Viola Andresen, Beverley Greenwood-Van Meerveld, Colin W. Howden, Angelo A. Izzo and Karen L. Jones Gastroenterology  Visualizza...

Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial

da admin | Nov 14, 2023 | RACCOLTA BIBLIOGRAFICA

Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial Christopher J. Martoni, Shalini Srivastava, Gregory J. Leyer Visualizza...
« Post precedenti

Articoli recenti

  • Global guidelines on diverticular disease of the colon: the Fiesole Consensus report
  • Gut microbiota in symptomatic uncomplicated diverticular disease stratifies by severity of abdominal pain
  • Micro-encapsulated and colonic-release sodium butyrate modulates gut microbiota and improves abdominal pain in patients with symptomatic uncomplicated diverticular disease
  • Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study
  • Rifaximin in diverticulosis and diverticular disease: a national survey among Italian gastroenterologists and general practitioners

Commenti recenti

    ideA-Z Project in progress S.r.l. | P.IVA: IT03373190960
    Corso Giacomo Matteotti, 48 – 20081 – Abbiategrasso (MI) | info@idea-z.it